HKU Study Promises New Treatment For Influenza
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "http://newsstatic.rthk.hk/audios/mfile_1401896_1_20180615154932.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','http://news.rthk.hk/rthk/en/component/k2/1401896-20180615.htm', 'DCS.dcsqry', '' ); } } }); }); });
2018-06-15 HKT 17:53
Hong Kong University researchers say they've achieved a world first in the fight against influenza, by curing infected mice using a doctored version of the flu virus.
Lead researcher Yuen Kwok-yung said this new kind of treatment promises to be more effective than existing drugs like Tamiflu or Relenza, which are only effective when administered within days of the patient falling ill, and for which viruses can quickly develop resistance.
The new treatment effectively turns the flu virus against itself. Researchers cuts away certain key genes from the virus, which prevents it from replicating normally. This 'defective interfering gene' treatment, dubbed DIG3, is therefore resistant to mutation because the virus recognises it as one of its own.
"The cell is being cheated... it's treated as the normal influenza virus. And so we do not expect mutations to develop against the defective interfering genes", Yuen said.
Another researcher, Kelvin To, said their study is the "first time in the world that defective interfering gene has been successfully demonstrated to cure mice from influenza."
"In this study, we have tested H7N7 and H1N1, but we believe that it should theoretically be able to fight against other subtypes of influenza viruses as well," he added.
However, researchers caution that it can take decades of development, clinical trials and adjustments, costing billions of dollars, before the technology can lead to new drugs actually being introduced to the market.
"We have a patent, and we're waiting for investors and companies to develop [the treatment] further in clinical trials et cetera. And we hope that, with the government's emphasis on innovation and technology, there would be money coming in to develop this into a marketable drug one day", Yuen said.
XTransfer Celebrates Milestone Of Over 1 Million Enterprise Clients
XTransfer shared that it has served more than one million enterprise clients since its founding in 2017. The B2B cross-... Read more
How Much Do Hong Kongs Biggest Banks Pay Their CEOs?
How much did it pay to run one of Hong Kong’s biggest banks in 2025? The answer varies sharply, and the numbers look ... Read more
DBS Hong Kong CEO Sebastian Paredes To Retire After 16 Years, Taiwan Chief Takes Over
Ng Sier Han will be the next DBS Hong Kong CEO. He takes over from Sebastian Paredes, who retires from executive duties... Read more
Hong Kong Founders Can Now Incorporate And Get Paid In One Application
Airwallex announced a corporate partnership with Air Corporate, a Hong Kong-based digital corporate service provider, i... Read more
Visa Tap To Pay Reaches Hong Kong Doorsteps In SF Express Deal
Visa announced a partnership with S.F. Express (Hong Kong) Limited (SFHK) to bring contactless card payment services to... Read more
Two Co-CEOs Take Over HSBC Insurance Leadership As Edward Moncreiffe Exits
HSBC has named two Asia-based executives as co-CEOs of its global insurance business. Daisy Tsang, CEO of HSBC Life Hon... Read more


